+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06534437

Study of MEN1703 Alone and With Glofitamab in Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Led by Ryvu Therapeutics SA · Updated on 2026-09-18

178

Participants Needed

35

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and anti-lymphoma activity of MEN1703 Dapolsertib hydrochloride, either alone or combined with glofitamab, in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. The study includes two groups one with patients who have not had anti-CD3xCD20 bispecific antibody therapy but have had at least two prior systemic treatments, and another with patients who have exhausted all standard treatment options. This is an open-label Phase 2 clinical trial with multiple study parts.

CONDITIONS

Brief Title

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Research Team

H

Head of Clinical Operations

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here